Health Technology · Pharmaceuticals: Major · NSE: AARTIDRUGS · data 2026-10-09
Aarti Drugs Limited
Health check: Average (5.7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹413.3
Market cap
₹3,788 cr
P/E
19.7
P/B
—
ROE
13.4%
ROCE
13.2%
Debt / equity
0.37
Dividend yield
0.48%
1-year return
-19.0%
52-week high
₹534
52-week low
₹318.95
Operating margin
9.8%
Growth
| Revenue (last 12 months) | ₹2,678 cr |
| Net profit (last 12 months) | ₹191 cr |
| Sales growth, 3 years (yearly) | -2.0% |
| Profit growth, 3 years (yearly) | 5.4% |
Chart patterns
- Double top — forming (key level ₹404.5)
Similar companies
SMS Pharmaceuticals Limited (SMSPHARMA) · Gufic Biosciences Limited (GUFICBIO) · Zota Health Care Ltd. (ZOTA) · Unichem Laboratories Limited (UNICHEMLAB) · Kwality Pharmaceuticals Ltd (KPL)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AARTIDRUGS in NSE Scanner →